Alnylam Pharmaceuticals Reports Record Q1 Revenue Driven by AMVUTTRA Growth
Alnylam Pharmaceuticals reported a historic milestone with over $1 billion in quarterly product revenue for Q1 2026, driven primarily by the global adoption of its drug AMVUTTRA. The company highlighted strong performance from its TTR franchise and reiterated full-year sales guidance between $4.4 billion to $4.7 billion.
Tickers: $ALNY
Topics: ATTR-CM clinical trials pharmaceuticals pipeline expansion revenue growth TTR franchise